Publications by authors named "K Cathie"
Article Synopsis
- - A study was conducted to evaluate the safety and effectiveness of nirsevimab, a monoclonal antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV) in healthy infants during their first RSV season.
- - Infants aged 12 months or younger who were born at least 29 weeks gestation were randomly assigned to receive either nirsevimab or standard care, with results showing that 0.3% in the nirsevimab group were hospitalized compared to 1.5% in the standard-care group, indicating an 83.2% efficacy for nirsevimab.
- - The study also found that severe cases of RSV were less common in the nirsevimab
Background: This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents.
Methods: A phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to November 2021, with follow-up visits to August 2022. Healthy 12-to-16 years olds were randomised (1:1:1) to either 30 µg BNT162b2 (BNT-30), 10 µg BNT162b2 (BNT-10), or NVX-CoV2373 (NVX), 8 weeks after a first 30 µg dose of BNT162b2.
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were subsequently widely used for the third and fourth-dose vaccination campaigns in high-income countries. Real-world vaccine effectiveness against symptomatic infections following third doses declined during the Omicron wave.
View Article and Find Full Text PDF